Clinical Trials Logo

Sporadic Angiomyolipomas (AMLs) clinical trials

View clinical trials related to Sporadic Angiomyolipomas (AMLs).

Filter by:
  • None
  • Page 1

NCT ID: NCT02539459 Terminated - Clinical trials for Sporadic Angiomyolipomas (AMLs)

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

SAGE
Start date: September 23, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.